212 related articles for article (PubMed ID: 17722162)
1. [From cocaine to innovative antiemetics. The medicinal chemistry of 5-ht3 receptor antagonists].
Zettl H; Schubert-Zsilavecz M; Siebert CD
Pharm Unserer Zeit; 2007; 36(5):354-61. PubMed ID: 17722162
[No Abstract] [Full Text] [Related]
2. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic drugs.
Cranwell-Bruce L
Medsurg Nurs; 2009; 18(5):309-13; quiz 314. PubMed ID: 19927970
[No Abstract] [Full Text] [Related]
4. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
5. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
Lee CY; Ratnapalan S; Thompson M; Nathan PC; Closs J; French A; Punnett A; Garcia-Bournissen F; Ito S; Koren G
Can J Clin Pharmacol; 2010; 17(1):e1-4. PubMed ID: 20051608
[TBL] [Abstract][Full Text] [Related]
6. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Hartvig P
J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570
[No Abstract] [Full Text] [Related]
7. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
Blower P; Aapro M
Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
[No Abstract] [Full Text] [Related]
8. NCCN antiemesis guidelines emphasize 'delayed' emesis, new 5-HT3 inhibitors, and NK-1 blockers.
National Comprehensive Cancer Network (NCCN)
J Support Oncol; 2004; 2(4):366. PubMed ID: 15357520
[No Abstract] [Full Text] [Related]
9. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
Scholz J
Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
[No Abstract] [Full Text] [Related]
10. Itasetron. DAU 6215, U 98079.
Drugs R D; 1999 Oct; 2(4):243-4. PubMed ID: 10659399
[No Abstract] [Full Text] [Related]
11. [Nausea and vomiting in oncologic therapy. Guidelines for use of setrone].
Nemec K
Pharm Unserer Zeit; 2007; 36(5):362-7. PubMed ID: 17722163
[No Abstract] [Full Text] [Related]
12. Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.
Gralla R
Clin Adv Hematol Oncol; 2006 Jul; 4(7):507-8. PubMed ID: 17147235
[No Abstract] [Full Text] [Related]
13. Site(s) and mechanisms of the anti-emetic action of 5-HT3 receptor antagonists: a discussion of Professor Naylor's paper.
Tyers MB
Br J Cancer Suppl; 1992 Dec; 19():S12-3. PubMed ID: 1467194
[No Abstract] [Full Text] [Related]
14. [History and new developments. The pharmacology of 5-ht3 antagonists].
Rex A; Bert B; Fink H
Pharm Unserer Zeit; 2007; 36(5):342-53. PubMed ID: 17722161
[No Abstract] [Full Text] [Related]
15. [Physiopathology, risk factors and therapy. Postoperative Nausea and vomiting (PONV)].
Wurglics M; Spiegl F
Pharm Unserer Zeit; 2007; 36(5):368-72. PubMed ID: 17722164
[No Abstract] [Full Text] [Related]
16. Blueprint for the control of radiation-induced nausea and vomiting. Discussion.
Horiot JC
Acta Oncol; 2004 Sep; 43 Suppl 15():23-4. PubMed ID: 15370627
[No Abstract] [Full Text] [Related]
17. [Type-3 serotonin receptor blockaders (5-HT3)--a new class of antiemetic preparations].
Legeza VI
Eksp Klin Farmakol; 1994; 57(4):72-5. PubMed ID: 7950795
[No Abstract] [Full Text] [Related]
18. [Navoban--the new 5HT3-antagonist].
Internist (Berl); 1994 May; 35(5 Suppl):1-8. PubMed ID: 9209536
[No Abstract] [Full Text] [Related]
19. Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.
Smaldone L; Plezia P; Alberts D; Aapro M; Sartiano G; Dorn M; Brady M; Comerski C; Schwartz SE; Fairchild C
Cancer Treat Rev; 1990 Sep; 17(2-3):319-27. PubMed ID: 2272047
[No Abstract] [Full Text] [Related]
20. Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients.
Yamada Y; Sugiura M; Higo K; Ozeki T; Takayanagi R; Okuyama K; Yamamoto K; Satoh H; Sawada Y; Iga T
Cancer Chemother Pharmacol; 2004 Aug; 54(2):185-90. PubMed ID: 15168080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
